Neoprobe Changes Name – Buys Rights to Alzheimer’s Diagnostic Drug

Neoprobe, which announced last week it will change its name to Navidea Biopharmaceuticals Inc. beginning next year, has also announced it has purchased worldwide rights to a drug that aids in the diagnosis of Alzheimer’s disease.  The drug, currently known as AZD4694, is used in brain imaging for patients who show signs of cognitive impairment, including Alzheimer’s.
 
Read the full story in Business First:
http://www.bizjournals.com/columbus/news/2011/12/13/neoprobe-buys-rights...